Search results
Results from the WOW.Com Content Network
Abuse of the drug or other substances may lead to severe psychological or physical dependence. The complete list of Schedule II substances is as follows. The Administrative Controlled Substances Code Number and Federal Register citation for each substance is included.
Short-term use increases the risk of minor and major adverse effects. [7] Common side effects include dizziness, feeling tired, vomiting, and hallucinations. [7] Long-term effects of cannabis are not clear. [7] Concerns include memory and cognition problems, risk of addiction, schizophrenia in young people, and the risk of children taking it by ...
It is presently classed in schedule I(C) along with its active constituents, the tetrahydrocannibinols and other psychotropic drugs. Some question has been raised whether the use of the plant itself produces "severe psychological or physical dependence" as required by a schedule I or even schedule II criterion. Since there is still a considerable void in our knowledge of the plant and the ...
On the positive side, a 2020 research article published in BMC Psychiatry concluded that there is "encouraging, albeit embryonic" (meaning, early stage) evidence for using medicinal cannabis to ...
The short-term effects of cannabis are caused by many chemical compounds in the cannabis plant, including 113 [clarification needed] different cannabinoids, such as tetrahydrocannabinol, and 120 terpenes, [1] which allow its drug to have various psychological and physiological effects on the human body.
American Legion, the nation's largest military veterans organization, passed a resolution at their September 2016 annual convention calling on Congress to remove cannabis from the list of Schedule I drugs. [134] In December 2016, the organization lobbied the incoming Trump administration to reclassify cannabis as a Schedule III drug. [135]
While marijuana has been decriminalized throughout many states in the US, it remains a Schedule I drug as of October 2024. However, on January 12, 2024, the FDA announced its recommendation that marijuana be moved to a Schedule III drug, which is a much less strictly-regulated category and would acknowledge its potential for medical use. [67]
Except when dispensed directly to an ultimate user by a practitioner other than a pharmacist, no controlled substance in Schedule II, which is a prescription drug as determined under the Federal Food, Drug, and Cosmetic Act (21 USC 301 et seq.), may be dispensed without the written or electronically transmitted (21 CFR 1306.08) prescription of ...